The first use of the PentraSorb® CRP after a myocardial infarction was published in the journal Case Reports Cardiology.

The article describes for the first time the treatment of a patient after an acute myocardial infarction (STEMI) with the PentraSorb® CRP. The patient was treated twice with immunapheresis and tolerated the treatment without side effects. The CRP concentration could be reduced by approx. 45%.